Related Experiment Videos
Beta-blockade in adriamycin-induced cardiomyopathy
A Noori1, J Lindenfeld, E Wolfel
1Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA.
Insights
Beta-blockers improve heart function in patients with Adriamycin-induced cardiomyopathy (ACM). This benefit is comparable to other forms of systolic dysfunction heart failure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockade therapy is known to improve myocardial systolic function in various cardiomyopathies.
- The efficacy of beta-blockade in Adriamycin-induced cardiomyopathy (ACM) remains unestablished.
Purpose of the Study:
- To evaluate the therapeutic effects of beta-blockade on cardiac function in patients diagnosed with Adriamycin-induced cardiomyopathy (ACM).
Main Methods:
- A retrospective case-controlled study design was employed.
- Patients with ACM receiving beta-blockers were compared to a control group of patients with idiopathic dilated cardiomyopathy (IDC) treated with beta-blockers.
- Left ventricular ejection fraction (LVEF) was assessed at baseline and after treatment.
Main Results:
- Patients with ACM showed a significant improvement in mean LVEF from 28% to 41% (P = .041) after beta-blocker treatment.
- The control group (IDC) demonstrated an LVEF improvement from 26% to 32% (P = .015).
- The degree of functional improvement was comparable between the ACM and IDC groups.
Conclusions:
- Beta-blockers exert a beneficial effect on cardiac function in patients suffering from Adriamycin-induced cardiomyopathy (ACM).
- The observed benefits are comparable to those seen in other forms of heart failure with systolic dysfunction.
Abstract:
Beta-blockade consistently improves myocardial systolic function in patients with both nonischemic and ischemic cardiomyopathy. The effects of beta-blockade on Adriamycin-induced cardiomyopathy (ACM), however, are unknown. We retrospectively evaluated the effects of beta-blockade on patients with ACM by using a case-controlled design. The control group consisted of 16 consecutively chosen age- and sex-matched patients with idiopathic dilated cardiomyopathy (IDC) who were treated with beta-blockers. Patients with ACM had a baseline mean left ventricular ejection fraction (LVEF) of 28%, which improved to 41% (P = .041) after treatment with beta-blockers. The control group had a baseline mean LVEF of 26%, which improved to 32% (P = .015) after treatment. The mean duration of beta-blocker therapy in the Adriamycin and control groups was 8 and 9 months, respectively. The degree of improvement between the 2 groups was not significantly different. Beta-blockers have a beneficial effect on cardiac function in patients with ACM, which is at least comparable with other forms of heart failure with systolic dysfunction.